LABID Drug Patent Profile
✉ Email this page to a colleague
When do Labid patents expire, and when can generic versions of Labid launch?
Labid is a drug marketed by Warner Chilcott and is included in one NDA.
The generic ingredient in LABID is theophylline. There are thirty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Labid
A generic version of LABID was approved as theophylline by RHODES PHARMS on September 1st, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LABID?
- What are the global sales for LABID?
- What is Average Wholesale Price for LABID?
Summary for LABID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 171 |
| Patent Applications: | 3,979 |
| DailyMed Link: | LABID at DailyMed |
US Patents and Regulatory Information for LABID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Warner Chilcott | LABID | theophylline | TABLET, EXTENDED RELEASE;ORAL | 087225-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
